MDB Capital Holdings’ PatentVest Maps IP Defenses Across 50 Oral GLP-1 Programs With $47B Deal Value
PatentVest, a division of MDB Capital Holdings, reviewed over 1,200 patent filings for 50 oral GLP-1 candidates, revealing major disparities in patent depth. With injectable GLP-1 sales at $71 billion and $47 billion in deals since 2023, report spotlights long-term exclusivity as semaglutide’s patent expires in 2031.
1. PatentVest Pulse Report Launch
MDB Capital Holdings’ PatentVest unit released the “Oral Small-Molecule GLP-1 Race: Beyond Orforglipron” report, analyzing over 1,200 patent filings across 50 oral GLP-1 programs and mapping claim scope for composition-of-matter, Markush, formulation, and method-of-use protections.
2. Market and Patent Analysis
The report highlights that injectable GLP-1 therapies built a $71 billion market while reaching under 5% of eligible patients, driving 50 oral small-molecule programs to pursue 12–16% weight-loss efficacy. It also details $47 billion in GLP-1 deal value since 2023 and dramatic disparities in patent depth among clinical-stage candidates.
3. Exclusivity and Franchise Potential
With semaglutide’s patent expiring in 2031 and tirzepatide’s in 2036, long-term exclusivity will hinge on robust patent portfolios and broad genus claims. Most oral programs remain unpartnered, making defensible IP positioning critical for future franchise value.